These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 16502485

  • 1. The combination of TRAIL treatment and cancer cell selective expression of TRAIL-death receptor DR4 induces cell death in TRAIL-resistant cancer cells.
    Choi E, Kim Y, Kim K.
    Yonsei Med J; 2006 Feb 28; 47(1):55-62. PubMed ID: 16502485
    [Abstract] [Full Text] [Related]

  • 2. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
    Kazhdan I, Marciniak RA.
    Cancer Gene Ther; 2004 Oct 28; 11(10):691-8. PubMed ID: 15354201
    [Abstract] [Full Text] [Related]

  • 3. Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
    Kurbanov BM, Geilen CC, Fecker LF, Orfanos CE, Eberle J.
    J Invest Dermatol; 2005 Nov 28; 125(5):1010-9. PubMed ID: 16297203
    [Abstract] [Full Text] [Related]

  • 4. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N, Poulaki V, Mitsiades C, Tsokos M.
    Cancer Res; 2001 Mar 15; 61(6):2704-12. PubMed ID: 11289151
    [Abstract] [Full Text] [Related]

  • 5. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer.
    Horak P, Pils D, Haller G, Pribill I, Roessler M, Tomek S, Horvat R, Zeillinger R, Zielinski C, Krainer M.
    Mol Cancer Res; 2005 Jun 15; 3(6):335-43. PubMed ID: 15972852
    [Abstract] [Full Text] [Related]

  • 6. Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter.
    Jacob D, Davis J, Zhu H, Zhang L, Teraishi F, Wu S, Marini FC, Fang B.
    Clin Cancer Res; 2004 May 15; 10(10):3535-41. PubMed ID: 15161713
    [Abstract] [Full Text] [Related]

  • 7. Molecular determinants of response to TRAIL in killing of normal and cancer cells.
    Kim K, Fisher MJ, Xu SQ, el-Deiry WS.
    Clin Cancer Res; 2000 Feb 15; 6(2):335-46. PubMed ID: 10690508
    [Abstract] [Full Text] [Related]

  • 8. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
    Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B, Schmid RA.
    Cancer Res; 2006 Jun 01; 66(11):5867-74. PubMed ID: 16740726
    [Abstract] [Full Text] [Related]

  • 9. [Killing effect of Ad.TERT-TRAIL on tumor cell lines and its mechanism].
    Tang YX, Chen Y, Gu JF, Qi R, Zou WG, Jiang LL, Liu XY.
    Ai Zheng; 2005 May 01; 24(5):536-42. PubMed ID: 15890093
    [Abstract] [Full Text] [Related]

  • 10. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
    Park SJ, Wu CH, Choi MR, Najafi F, Emami A, Safa AR.
    Biochem Pharmacol; 2006 Jul 28; 72(3):293-307. PubMed ID: 16753135
    [Abstract] [Full Text] [Related]

  • 11. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jégou B, Patard JJ, Guillaudeux T.
    Prostate; 2006 Jun 15; 66(9):987-95. PubMed ID: 16541419
    [Abstract] [Full Text] [Related]

  • 12. Enforced expression of a truncated form of Bax-alpha (tBax) driven by human telomerase reverse transcriptase (hTERT) promoter sensitizes tumor cells to chemotherapeutic agents or tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
    Toyota H, Kondo S, Kyo S, Mizuguchi J.
    Anticancer Res; 2006 Jun 15; 26(1A):99-105. PubMed ID: 16475685
    [Abstract] [Full Text] [Related]

  • 13. Cancer gene therapy using a novel secretable trimeric TRAIL.
    Kim CY, Jeong M, Mushiake H, Kim BM, Kim WB, Ko JP, Kim MH, Kim M, Kim TH, Robbins PD, Billiar TR, Seol DW.
    Gene Ther; 2006 Feb 15; 13(4):330-8. PubMed ID: 16195699
    [Abstract] [Full Text] [Related]

  • 14. eNOS protects prostate cancer cells from TRAIL-induced apoptosis.
    Tong X, Li H.
    Cancer Lett; 2004 Jul 08; 210(1):63-71. PubMed ID: 15172122
    [Abstract] [Full Text] [Related]

  • 15. Alpha-tocopheryl succinate induces DR4 and DR5 expression by a p53-dependent route: implication for sensitisation of resistant cancer cells to TRAIL apoptosis.
    Tomasetti M, Andera L, Alleva R, Borghi B, Neuzil J, Procopio A.
    FEBS Lett; 2006 Apr 03; 580(8):1925-31. PubMed ID: 16529749
    [Abstract] [Full Text] [Related]

  • 16. Cisplatin enhances apoptosis induced by a tumor-selective adenovirus expressing tumor necrosis factor-related apoptosis-inducing ligand.
    Reddy RM, Tsai WS, Ziauddin MF, Zuo J, Cole GW, Maxhimer JB, Fang B, Schrump DS, Nguyen DM.
    J Thorac Cardiovasc Surg; 2004 Dec 03; 128(6):883-91. PubMed ID: 15573073
    [Abstract] [Full Text] [Related]

  • 17. Fiber-modified adenoviral vector expressing the tumor necrosis factor-related apoptosis-inducing ligand gene from the human telomerase reverse transcriptase promoter induces apoptosis in human hepatocellular carcinoma cells.
    Jacob D, Schumacher G, Bahra M, Davis J, Zhu HB, Zhang LD, Teraishi F, Neuhaus P, Fang BL.
    World J Gastroenterol; 2005 May 07; 11(17):2552-6. PubMed ID: 15849810
    [Abstract] [Full Text] [Related]

  • 18. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
    Earel JK, VanOosten RL, Griffith TS.
    Cancer Res; 2006 Jan 01; 66(1):499-507. PubMed ID: 16397266
    [Abstract] [Full Text] [Related]

  • 19. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
    Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN.
    Cancer Res; 2001 Jan 15; 61(2):759-63. PubMed ID: 11212279
    [Abstract] [Full Text] [Related]

  • 20. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR, Shankar S, Chen X, Asim M, Srivastava RK.
    Cancer Res; 2003 Sep 01; 63(17):5390-400. PubMed ID: 14500373
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.